<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02584582</url>
  </required_header>
  <id_info>
    <org_study_id>H-3-2014-128</org_study_id>
    <nct_id>NCT02584582</nct_id>
  </id_info>
  <brief_title>The Effect of GLP-1 on Postprandial Glucagon Secretion Independent of The Gastric Emptying Rate</brief_title>
  <acronym>ALFA-1</acronym>
  <official_title>The Effect of GLP-1 on Postprandial Glucagon Secretion During Prolonged and Intermittent Stimulation of the GLP-1 Receptor Independent of The Gastric Emptying Rate. A Randomized, Open-label Study in People With Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hvidovre University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hvidovre University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim: To investigate the glucagonostatic effect of glucagon-like peptide-1 (GLP-1) independent
      of the gastric emptying rate.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aim: To investigate the glucagonostatic effects of glucagon-like peptide-1 (GLP-1) during
      prolonged and intermittent stimulation of the GLP-1 receptor independent of the gastric
      emptying rate. Glucagon concentrations will be measured following a liquid meal administered
      in duodenum at baseline and after exenatide, and liraglutide treatment.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date>July 2015</start_date>
  <primary_completion_date type="Anticipated">November 2015</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glucagon concentration (postprandial)</measure>
    <time_frame>4 hours</time_frame>
    <description>glucagon area under the curve (AUC) (0-240 minutes) and baseline to peak increments will be calculated</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postprandial glucose concentrations</measure>
    <time_frame>4 hours</time_frame>
    <description>glucose AUC (0-240 minutes) and baseline to peak increments will be calculated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>glucagon-like peptide-1 (GLP-1)</measure>
    <time_frame>4 hours</time_frame>
    <description>GLP-1 AUC (0-240 minutes) and baseline to peak increments will be calculated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>glucagon-like peptide-2 (GLP-2)</measure>
    <time_frame>4 hours</time_frame>
    <description>GLP-2 AUC (0-240 minutes) and baseline to peak increments will be calculated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>glucose-dependent insulinotropic polypeptide (GIP)</measure>
    <time_frame>4 hours</time_frame>
    <description>GIP AUC (0-240 minutes) and baseline to peak increments will be calculated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cholecystokinin (CCK)</measure>
    <time_frame>4 hours</time_frame>
    <description>CCKAUC (0-240 minutes) and baseline to peak increments will be calculated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peptide YY (PYY)</measure>
    <time_frame>4 hours</time_frame>
    <description>PYY AUC (0-240 minutes) and baseline to peak increments will be calculated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ghrelin</measure>
    <time_frame>4 hours</time_frame>
    <description>Ghrelin AUC (0-240 minutes) and baseline to peak increments will be calculated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastrin</measure>
    <time_frame>4 hours</time_frame>
    <description>Gastrin AUC (0-240 minutes) and baseline to peak increments will be calculated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxyntomodulin</measure>
    <time_frame>4 hours</time_frame>
    <description>Oxyntomodulin AUC (0-240 minutes) and baseline to peak increments will be calculated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Free fatty acids (FFA)</measure>
    <time_frame>4 hours</time_frame>
    <description>FFA AUC (0-240 minutes) and baseline to peak increments will be calculated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>triacylglycerol (TAG)</measure>
    <time_frame>4 hours</time_frame>
    <description>TAG AUC (0-240 minutes) and baseline to peak increments will be calculated</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>Liraglutide + Liquid meal test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Liraglutide 1.2 mg once daily for 14 days (0.6 mg/day for one week, escalated to 1.2 mg/day after one week)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Exenatide + Liquid meal test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Exenatide 10 mcg twice daily for 14 days (5 mcg twice daily for one week, escalated to 10 mcg twice daily after one week)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Baseline + Liquid meal test</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Baseline day with no additional medication</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liraglutide</intervention_name>
    <arm_group_label>Liraglutide + Liquid meal test</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exenatide</intervention_name>
    <arm_group_label>Exenatide + Liquid meal test</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Liquid meal test</intervention_name>
    <arm_group_label>Liraglutide + Liquid meal test</arm_group_label>
    <arm_group_label>Exenatide + Liquid meal test</arm_group_label>
    <arm_group_label>Baseline + Liquid meal test</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No drug (Baseline day)</intervention_name>
    <arm_group_label>Baseline + Liquid meal test</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 1 Diabetes

          -  &gt;18 years

          -  No residual beta-cell function (stimulated C-peptide &lt; 60 pmol)

        Exclusion Criteria:

          -  Pancreatitis

          -  gastroparesis

          -  history of alcohol and/or drug abuse

          -  pregnancy and lactation

          -  other medical or psychological condition that made the patient unsuitable for study
             participation according to the investigatorsÂ´ assessment

          -  contraindications to gastroscopy

          -  cancer (unless in complete remission &gt; five years)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 6, 2015</study_first_submitted>
  <study_first_submitted_qc>October 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 22, 2015</study_first_posted>
  <last_update_submitted>October 21, 2015</last_update_submitted>
  <last_update_submitted_qc>October 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hvidovre University Hospital</investigator_affiliation>
    <investigator_full_name>Christan SS Frandsen, MD</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Glucagon</keyword>
  <keyword>Glukagon-like peptide-1 (GLP-1)</keyword>
  <keyword>GLP-1 receptor agonist (GLP-1RA)</keyword>
  <keyword>Incretins</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Exenatide</mesh_term>
    <mesh_term>Liraglutide</mesh_term>
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
    <mesh_term>Glucagon</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

